Author

Laura Rae Parham

Observed names: L R Parham, L.R. Parham, LR Parham, Laura Parham, Laura R Parham, Laura R. Parham

Institutions: GlaxoSmithKline (United States), PAREXEL International (United States)

Observed institutions: Mayo Clinic, GlaxoSmithKline (United Kingdom), Rigshospitalet, Massachusetts General Hospital, GlaxoSmithKline (United States), PAREXEL International (United States)

ORCID: 0000-0002-2795-9831

Observed ORCID: 0000-0002-2795-9831

OpenAlex ID: A5027622397

Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury

2014 · Daniel J. Schaid, Colin F. Spraggs, et al. · Journal of Clinical Oncology · 74

Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01

2015 · L R Parham, L P Briley, et al. · The Pharmacogenomics Journal · 63

A Randomized Phase 2 Study of an Anti–Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular Degeneration

2018 · Philip J. Rosenfeld, Brian Berger, et al. · Ophthalmology Retina · 58

Lapatinib-Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes

2012 · C F Spraggs, L R Parham, et al. · Clinical Pharmacology & Therapeutics · 49

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis

2020 · Lynn D. Condreay, Laura R. Parham, et al. · Rheumatology International · 29

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

2017 · C F Spraggs, L R Parham, et al. · The Pharmacogenomics Journal · 20

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir

2020 · Parul Patel, Zhengyu Xue, et al. · Journal of Antimicrobial Chemotherapy · 11

Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib

2015 · C.F. Spraggs, L.R. Parham, et al. · Annals of Oncology · 3

HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO.

2015 · Colin F. Spraggs, Laura Rae Parham, et al. · Journal of Clinical Oncology · 2

Abstract PD10-05: HLA-DQA1*02:01/DRB1*07:01 as a biomarker for lapatinib-induced hepatotoxicity: prospective confirmation in a large randomised clinical trial (TEACH, EGF105485)

2012 · CF Spraggs, DJ Schaid, et al. · Cancer Research · 2

Rash in Lapatinib-Treated Patients is not Associated With Human Leukocyte Antigen Polymorphisms

2015 · Laura R Parham, Linda P Briley, et al. · Pharmacogenomics · 1

Evaluation of pro-apoptotic BIM gene loss of function on lapatinib efficacy in patients with metastatic breast cancer (MBC) and in HER2-amplified cell lines.

2014 · Colin F. Spraggs, Linda P Briley, et al. · Journal of Clinical Oncology

VEGF polymorphism may be associated with overall survival in lapatinib-treated breast cancer patients with brain metastases.

2012 · Colin F. Spraggs, Li Li, et al. · Journal of Clinical Oncology

Works count: 13

Citation count: 311

H-index: 7

I10-index: 7